Sostdc1 Suppression in the Absence of Sclerostin Potentiates Anabolic Action of Cortical Bone in Mice
暂无分享,去创建一个
G. Loots | A. Robling | A. Hoggatt | D. Horan | Emily Z. Rogers | R. Choi
[1] A. Robling,et al. Targeting Sclerostin and Dkk1 at Optimized Proportions of Low-Dose Antibody Achieves Similar Skeletal Benefits to Higher-Dose Sclerostin Targeting in the Mature Adult and Aged Skeleton , 2022, Aging and disease.
[2] A. Robling,et al. Notum Deletion From Late‐Stage Skeletal Cells Increases Cortical Bone Formation and Potentiates Skeletal Effects of Sclerostin Inhibition , 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] N. Sims,et al. Cortical bone development, maintenance and porosity: genetic alterations in humans and mice influencing chondrocytes, osteoclasts, osteoblasts and osteocytes , 2021, Cellular and Molecular Life Sciences.
[4] G. Loots,et al. Improving Bone Health by Optimizing the Anabolic Action of Wnt Inhibitor Multitargeting , 2021, JBMR plus.
[5] Chandramohan Kattamuri,et al. Characterization of the different oligomeric states of the DAN family antagonists SOSTDC1 and SOST , 2020, The Biochemical journal.
[6] S. Edwards,et al. Evolution of the DAN gene family in vertebrates , 2019, bioRxiv.
[7] G. Loots,et al. Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In Vivo , 2019, iScience.
[8] P. Croucher,et al. Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells , 2019, Bone.
[9] A. Robling,et al. Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism. , 2019, Bone.
[10] R. Krumlauf,et al. Shh Plays an Inhibitory Role in Cusp Patterning by Regulation of Sostdc1 , 2018, Journal of dental research.
[11] G. Loots,et al. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition. , 2018, JCI insight.
[12] Motoko Yanagita,et al. Antagonistic Functions of USAG-1 and RUNX2 during Tooth Development , 2016, PloS one.
[13] G. Loots,et al. Sostdc1 deficiency accelerates fracture healing by promoting the expansion of periosteal mesenchymal stem cells. , 2016, Bone.
[14] Brian J. Stevenson,et al. Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease. , 2016, The New England journal of medicine.
[15] W. Richards,et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair , 2016, Nature Communications.
[16] C. Camargo,et al. US population aging and demand for inpatient services. , 2014, Journal of hospital medicine.
[17] Peter Willett,et al. What is a tutorial , 2013 .
[18] Joseph M. Cruz,et al. Conditionals by inversion provide a universal method for the generation of conditional alleles , 2013, Proceedings of the National Academy of Sciences.
[19] T. Mueller,et al. Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling , 2013, PloS one.
[20] J. Kanis,et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] David M. Evans,et al. WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk , 2012, PLoS genetics.
[22] L. Carbone. Pain management standards in the eighth edition of the Guide for the Care and Use of Laboratory Animals. , 2012, Journal of the American Association for Laboratory Animal Science : JAALAS.
[23] Zhenlin Zhang,et al. Contribution of the sclerostin domain-containing protein 1 (SOSTDC1) gene to normal variation of peak bone mineral density in Chinese women and men , 2011, Journal of Bone and Mineral Metabolism.
[24] P. Kostenuik,et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] R. Krumlauf,et al. Inhibition of Wnt signaling by Wise (Sostdc1) and negative feedback from Shh controls tooth number and patterning , 2010, Development.
[26] Ralph Müller,et al. Guidelines for assessment of bone microstructure in rodents using micro–computed tomography , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] G. Loots,et al. Genetic evidence that SOST inhibits WNT signaling in the limb. , 2010, Developmental biology.
[28] T. Sakurai,et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. , 2010, The Journal of clinical investigation.
[29] M. Ota,et al. Lrp4 Modulates Extracellular Integration of Cell Signaling Pathways in Development , 2008, PloS one.
[30] Scott Saunders,et al. Bone Density Ligand, Sclerostin, Directly Interacts With LRP5 but Not LRP5G171V to Modulate Wnt Activity , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] Katsu Takahashi,et al. Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. , 2005, The Journal of clinical investigation.
[32] Nobuyuki Itoh,et al. Regulation of Mammalian Tooth Cusp Patterning by Ectodin , 2005, Science.
[33] A. Niida,et al. USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney. , 2004, Biochemical and biophysical research communications.
[34] Nobuyuki Itoh,et al. Sclerostin Is a Novel Secreted Osteoclast-derived Bone Morphogenetic Protein Antagonist with Unique Ligand Specificity* , 2003, Journal of Biological Chemistry.
[35] C H Turner,et al. Basic biomechanical measurements of bone: a tutorial. , 1993, Bone.